These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 34486981)

  • 21. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
    Younossi ZM; Koenig AB; Abdelatif D; Fazel Y; Henry L; Wymer M
    Hepatology; 2016 Jul; 64(1):73-84. PubMed ID: 26707365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pediatric nonalcoholic fatty liver disease: overview with emphasis on histology.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2010 Nov; 16(42):5280-5. PubMed ID: 21072890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: a study in Brazilian patients.
    Domenici FA; Brochado MJ; Martinelli Ade L; Zucoloto S; da Cunha SF; Vannucchi H
    Gene; 2013 Oct; 529(2):326-31. PubMed ID: 23891824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
    Budd J; Cusi K
    Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pediatric nonalcoholic fatty liver disease/nonalcoholic steatohepatitis].
    Takahashi Y; Fukusato T; Inui A; Fujisawa T
    Nihon Rinsho; 2012 Oct; 70(10):1827-34. PubMed ID: 23198569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
    Younossi ZM; Tampi RP; Racila A; Qiu Y; Burns L; Younossi I; Nader F
    Diabetes Care; 2020 Feb; 43(2):283-289. PubMed ID: 31658974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonalcoholic Fatty Liver Disease: Clinical Features and Pathogenesis.
    Basaranoglu M; Neuschwander-Tetri BA
    Gastroenterol Hepatol (N Y); 2006 Apr; 2(4):282-291. PubMed ID: 28286458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
    Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
    Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Soejima Y; Fukusato T
    World J Gastroenterol; 2012 May; 18(19):2300-8. PubMed ID: 22654421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
    Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonalcoholic Fatty Liver Disease and Its Complex Relation with Type 2 Diabetes Mellitus-From Prevalence to Diagnostic Approach and Treatment Strategies.
    Diaconu CT; Guja C
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36079070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030.
    Alswat K; Aljumah AA; Sanai FM; Abaalkhail F; Alghamdi M; Al Hamoudi WK; Al Khathlan A; Al Quraishi H; Al Rifai A; Al Zaabi M; Babatin MA; Estes C; Hashim A; Razavi H
    Saudi J Gastroenterol; 2018; 24(4):211-219. PubMed ID: 29956688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD).
    Lomonaco R; Chen J; Cusi K
    Ther Adv Endocrinol Metab; 2011 Oct; 2(5):211-25. PubMed ID: 23148186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gender and racial differences in nonalcoholic fatty liver disease.
    Pan JJ; Fallon MB
    World J Hepatol; 2014 May; 6(5):274-83. PubMed ID: 24868321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment options for nonalcoholic fatty liver disease.
    Lam B; Younossi ZM
    Therap Adv Gastroenterol; 2010 Mar; 3(2):121-37. PubMed ID: 21180596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Mechanism Analysis and Prevention of Pathogenesis of Nonalcoholic Steatohepatitis].
    Nakajima T; Naito H
    Nihon Eiseigaku Zasshi; 2015; 70(3):197-204. PubMed ID: 26411937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.
    Pydyn N; Miękus K; Jura J; Kotlinowski J
    Pharmacol Rep; 2020 Feb; 72(1):1-12. PubMed ID: 32016853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective.
    Samji NS; Verma R; Satapathy SK
    J Clin Exp Hepatol; 2019; 9(4):497-505. PubMed ID: 31516266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.